You are here:

nevirapine (Viramune)

Advice

Following an abbreviated submission:
 
nevirapine prolonged release tablets (Viramune®) are accepted for use in NHS Scotland.
 
Indication under review: in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets.
 
Once daily dosing with the nevirapine prolonged release formulation demonstrated non-inferior efficacy to the immediate release nevirapine formulation at 48 weeks in both treatment-naïve and treatment-experienced patients. When combined with other HIV therapies the once daily formulation may provide a more convenient dosing schedule for patients.

Drug Details

Drug Name: nevirapine (Viramune)
SMC Drug ID: 760/12
Manufacturer: Boehringer Ingelheim Ltd
Indication: In combination with other anti-retroviral medicinal products, for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 13 February 2012

Back